Showing results (81-90 of 93) with videos related to
Sort By:
Pageof 10
European Journal of Medicinal Chemistry|July 24, 2017
Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agentsRaymond J Patch, Hui Huang, Sharmila Patel, et al.Bioorganic & Medicinal Chemistry Letters|July 26, 2008
4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitorsGuozhang Xu, Marta C Abad, Peter J Connolly, et al.International Journal of Environmental Research and Public Health|March 25, 2017
Perceptions of Health Co-Benefits in Relation to Greenhouse Gas Emission Reductions: A Survey among Urban Residents in Three Chinese CitiesJinghong Gao, Guozhang Xu, Wenjun Ma, et al.The American Journal of Gastroenterology|October 21, 2010
Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinomaJianhua Yin, Jiaxin Xie, Shijian Liu, et al.Plos Neglected Tropical Diseases|August 16, 2019
Incidence dynamics and investigation of key interventions in a dengue outbreak in Ningbo City, ChinaBo Yi, Yi Chen, Xiao Ma, et al.Journal of Medicinal Chemistry|November 21, 2024
Discovery of Potent, Highly Selective, and Efficacious SMARCA2 DegradersZhenwu Li, Lalgudi S Harikrishnan, Guozhang Xu, et al.JAMA Internal Medicine|September 2, 2020
Community Outbreak Investigation of SARS-CoV-2 Transmission Among Bus Riders in Eastern ChinaYe Shen, Changwei Li, Hongjun Dong, et al.Bioorganic & Medicinal Chemistry Letters|April 19, 2008
Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motifKevin D Kreutter, Tianbao Lu, Lily Lee, et al.Bioorganic & Medicinal Chemistry Letters|May 30, 2008
Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinasesGuozhang Xu, Lily Lee Searle, Terry V Hughes, et al.Journal of Medicinal Chemistry|November 1, 2024
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast CancerRanjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.Pageof 10